Anyone who tells you that there's no such thing as bad publicity never worked in the pharma business. A new survey shows that GlaxoSmithKline ($GSK) and some of its pharma rivals have seen their negative ratings soar in the wake of damaging admissions as patients lose faith with some of the biggest drug peddlers. Running against the trend: Gilead ($GILD) and Lundbeck, which got top marks for transparency and integrity. Novartis ($NVS) came in third. Story